雌激素与乳腺癌：肥胖相关发展、生长和进展涉及的机制。
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.
机构信息
Department of Medicine, Weill Cornell Medicine, New York, USA; Graduate School of Medical Sciences, Weill Cornell Medicine, New York, USA.
Department of Medicine, Weill Cornell Medicine, New York, USA.
出版信息
J Steroid Biochem Mol Biol. 2019 May;189:161-170. doi: 10.1016/j.jsbmb.2019.03.002. Epub 2019 Mar 6.
Abstract
Obesity is a risk factor for estrogen receptor-positive (ER+) breast cancer after menopause. The pro-proliferative effects of estrogens are well characterized and there is a growing body of evidence to also suggest an important role in tumorigenesis. Importantly, obesity not only increases the risk of breast cancer, but it also increases the risk of recurrence and cancer-associated death. Aromatase is the rate-limiting enzyme in estrogen biosynthesis and its expression in breast adipose stromal cells is hypothesized to drive the growth of breast tumors and confer resistance to endocrine therapy in obese postmenopausal women. The molecular regulation of aromatase has been characterized in response to many obesity-related molecules, including inflammatory mediators and adipokines. This review is aimed at providing an overview of our current knowledge in relation to the regulation of estrogens in adipose tissue and their role in driving breast tumor development, growth and progression.
摘要
肥胖是绝经后雌激素受体阳性（ER+）乳腺癌的一个危险因素。雌激素的促增殖作用已得到充分证实，越来越多的证据表明其在肿瘤发生中也起着重要作用。重要的是，肥胖不仅会增加乳腺癌的风险，还会增加复发和与癌症相关的死亡风险。芳香化酶是雌激素生物合成的限速酶，其在乳腺脂肪基质细胞中的表达被假设为驱动乳腺肿瘤的生长，并使肥胖绝经后妇女对内分泌治疗产生耐药性。芳香化酶的分子调节已经针对许多与肥胖相关的分子进行了描述，包括炎症介质和脂肪因子。这篇综述旨在概述我们目前在脂肪组织中雌激素的调节及其在驱动乳腺肿瘤发生、生长和进展中的作用方面的知识。
相似文献
1
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.雌激素与乳腺癌：肥胖相关发展、生长和进展涉及的机制。
J Steroid Biochem Mol Biol. 2019 May;189:161-170. doi: 10.1016/j.jsbmb.2019.03.002. Epub 2019 Mar 6.
2
Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer.功能失调的脂肪组织中芳香化酶的过度表达将肥胖与绝经后乳腺癌联系起来。
J Steroid Biochem Mol Biol. 2015 Sep;153:35-44. doi: 10.1016/j.jsbmb.2015.07.008. Epub 2015 Jul 21.
3
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.成纤维细胞生长因子受体 1（FGFR1）是雌激素剥夺后肥胖相关的雌激素受体阳性乳腺癌进展的基础。
JCI Insight. 2018 Jul 26;3(14). doi: 10.1172/jci.insight.120594.
4
Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer.肥胖与乳腺癌中的炎症、代谢失调及芳香化酶
Curr Opin Pharmacol. 2016 Dec;31:90-96. doi: 10.1016/j.coph.2016.11.003. Epub 2016 Nov 19.
5
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.肥胖与乳腺癌——雌激素的作用及芳香化酶在乳腺脂肪组织中的调控机制。
Mol Cell Endocrinol. 2018 May 5;466:15-30. doi: 10.1016/j.mce.2017.09.014. Epub 2017 Sep 15.
6
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.人骨微环境中的局部雌激素轴调节雌激素受体阳性乳腺癌细胞。
Breast Cancer Res. 2017 Nov 15;19(1):121. doi: 10.1186/s13058-017-0910-x.
7
Aromatase, breast cancer and obesity: a complex interaction.芳香化酶、乳腺癌与肥胖：复杂的相互作用。
Trends Endocrinol Metab. 2012 Feb;23(2):83-9. doi: 10.1016/j.tem.2011.10.003. Epub 2011 Dec 12.
8
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.肥胖女性来源的乳腺脂肪基质细胞在器官型乳腺模型中降低对芳香酶抑制剂阿那曲唑的敏感性。
FASEB J. 2019 Jul;33(7):8623-8633. doi: 10.1096/fj.201802347RRR. Epub 2019 Apr 19.
9
Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways.肥胖相关的脂肪干细胞生物学改变通过雌激素依赖途径介导肿瘤发生增强。
Breast Cancer Res. 2013;15(5):R102. doi: 10.1186/bcr3569.
10
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.人类乳腺癌中通过雌激素信号通路的肿瘤-基质相互作用。
Cancer Res. 2005 Jun 1;65(11):4653-62. doi: 10.1158/0008-5472.CAN-04-3236.
引用本文的文献
1
Interplay of obesity and parasitic infection: current evidence of immunogenesis, tumorigenesis and leptin receptor involvement.肥胖与寄生虫感染的相互作用：免疫发生、肿瘤发生及瘦素受体参与的当前证据
Nutr Metab (Lond). 2025 Sep 15;22(1):105. doi: 10.1186/s12986-025-00972-7.
2
The global, regional, and national disease burden of breast cancer attributable to behavioral risks from 1990 to 2021 and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021.1990年至2021年及2035年预测期间，归因于行为风险的全球、区域和国家乳腺癌疾病负担：全球疾病负担研究2021的系统分析
Breast Cancer. 2025 Aug 30. doi: 10.1007/s12282-025-01771-x.
3
Unraveling the Role of Metabolic Endotoxemia in Accelerating Breast Tumor Progression.解析代谢性内毒素血症在加速乳腺肿瘤进展中的作用
Biomedicines. 2025 Jul 31;13(8):1868. doi: 10.3390/biomedicines13081868.
4
Breast Cancer Cytochromes P450: Chemopreventive and/or Therapeutic Targets for Naturally Occurring Phytochemicals.乳腺癌细胞色素P450：天然植物化学物质的化学预防和/或治疗靶点
Molecules. 2025 Jul 23;30(15):3079. doi: 10.3390/molecules30153079.
5
PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.PCAIs可刺激芳香化酶抑制剂耐药乳腺癌细胞中的丝裂原活化蛋白激酶（MAPK）、磷脂酰肌醇-3激酶/蛋白激酶B（PI3K/AKT）信号通路以及活性氧（ROS）介导的细胞凋亡，同时破坏肌动蛋白丝和粘着斑。
Oncotarget. 2025 Jul 29;16:621-641. doi: 10.18632/oncotarget.28759.
6
Interactions Among Tumor Subtype, PPARγ Expression, and Adipose Proliferation Shape Outcomes in Breast Cancer.肿瘤亚型、PPARγ表达与脂肪增殖之间的相互作用影响乳腺癌预后
medRxiv. 2025 Jul 8:2025.07.08.25331111. doi: 10.1101/2025.07.08.25331111.
7
Development of an HPLC-FLD Method for Estradiol and Metabolites: Application of Solid-Phase Microextraction.一种用于雌二醇及其代谢物的高效液相色谱-荧光检测法的开发：固相微萃取的应用
Int J Mol Sci. 2025 Jun 27;26(13):6194. doi: 10.3390/ijms26136194.
8
Association of anthropometric indices with rs9939609 gene polymorphism among overweight/obese women with breast cancer: a case-control study.超重/肥胖乳腺癌女性人体测量指数与rs9939609基因多态性的关联：一项病例对照研究。
Front Nutr. 2025 Jun 24;12:1548340. doi: 10.3389/fnut.2025.1548340. eCollection 2025.
9
Adjuvant melatonin therapy during exercise prescription in breast cancer survivors on physical and anthropometric parameters, quality of life, and hormonal response. A randomized controlled trial.辅助褪黑素疗法对乳腺癌幸存者运动处方期间身体和人体测量参数、生活质量及激素反应的影响：一项随机对照试验
Front Sports Act Living. 2025 Jun 23;7:1594733. doi: 10.3389/fspor.2025.1594733. eCollection 2025.
10
Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.1990年至2021年50岁及以上女性子宫癌的全球、区域和国家负担：全球疾病负担研究2021的系统分析
J Health Popul Nutr. 2025 Jun 18;44(1):208. doi: 10.1186/s41043-025-00915-1.
本文引用的文献
1
Prostaglandin E down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.前列腺素 E 下调 SIRT1（沉默调节蛋白 1），导致芳香酶水平升高，为肥胖与乳腺癌的关联提供了新的见解。
J Biol Chem. 2019 Jan 4;294(1):361-371. doi: 10.1074/jbc.RA118.005866. Epub 2018 Nov 8.
2
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.成纤维细胞生长因子受体 1（FGFR1）是雌激素剥夺后肥胖相关的雌激素受体阳性乳腺癌进展的基础。
JCI Insight. 2018 Jul 26;3(14). doi: 10.1172/jci.insight.120594.
3
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study.体重指数对转移性乳腺癌患者内分泌治疗疗效的影响——一项回顾性的两中心队列研究。
Breast. 2018 Aug;40:136-140. doi: 10.1016/j.breast.2018.05.005. Epub 2018 May 18.
4
Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer.肥胖与接受来曲唑辅助治疗的绝经后乳腺癌女性的预后
Ecancermedicalscience. 2018 Mar 26;12:821. doi: 10.3332/ecancer.2018.821. eCollection 2018.
5
On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases.论乳癌不可手术病例的治疗：一种新治疗方法的建议及实例说明
Trans Med Chir Soc Edinb. 1896;15:153-179.
6
IL-10 suppresses TNF-α-induced expression of human aromatase gene in mammary adipose tissue.IL-10 抑制 TNF-α 诱导的人乳腺脂肪组织芳香化酶基因表达。
FASEB J. 2018 Jun;32(6):3361-3370. doi: 10.1096/fj.201700938RRR. Epub 2018 Jan 23.
7
Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.瘦素调节脂肪基质细胞中 p53-HIF1α/PKM2-芳香酶轴：肥胖与乳腺癌关联的新机制。
Int J Obes (Lond). 2018 Apr;42(4):711-720. doi: 10.1038/ijo.2017.273. Epub 2017 Nov 6.
8
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER Breast Cancer.成纤维细胞生长因子受体 1（FGFR1）与雌激素受体α（ERα）的关联维持了配体非依赖性 ER 转录，并介导了 ER 阳性乳腺癌对雌激素剥夺的耐药性。
Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27.
9
Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers.绝经是乳腺芳香化酶表达的一个决定因素及其与体重指数、炎症和全身标志物的关联。
J Clin Endocrinol Metab. 2017 May 1;102(5):1692-1701. doi: 10.1210/jc.2016-3606.
10
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.正常体重指数女性的代谢性肥胖、脂肪炎症与乳腺芳香化酶升高
Cancer Prev Res (Phila). 2017 Apr;10(4):235-243. doi: 10.1158/1940-6207.CAPR-16-0314. Epub 2017 Mar 7.
Zotero 插件